Patent ID: 7838531

Claim:
A method of reducing at least one cellular defect in a cell from a subject having a disease or condition selected from the group consisting of Hutchinson-Gilford Progeria Syndrome, progeria, Emery-Dreifuss muscular dystrophy, Limb-Girdle muscular dystrophy, Charcot-Marie-Tooth disorder, Werner syndrome, and dilated cardiomyopathy with conduction system disease, wherein the cellular defect is one or more cellular defects selected from the group consisting of mis-localization of a farnesylated lamin, mis-localization of a non-farnesylated lamin, nuclear membrane disruption, aggregation of lamin, nuclear lobulation, nuclear blebbing, cytoskeleton disruption, early senescence, premature apoptosis, and reduced secretion of MMP-3; the method comprising administering to the cell a therapeutically effective dose of a farnesyltransferase inhibitor (FTI).